

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re the application of: M. Alexandra Glucksmann *et al.*

Serial No.: N/A

Filed: Herewith

For: *14273 RECEPTOR, A NOVEL G-PROTEIN COUPLED RECEPTOR*

Attorney Docket No.: MNI-204CP2DV1

Group Art Unit: 1646

Examiner: Brannock, M.

Commissioner for Patents
Box Patent Application
Washington, D.C. 20231

CERTIFICATION UNDER 37 CFR 1.10

Date of Deposit: February 13, 2002

Mailing Label Number: EL 892 199 437 US

I hereby certify that this 37 CFR 1.53(b) request and the documents referred to as attached therein are being deposited with the United States Postal Service on the date indicated above in an envelope as "Express Mail Post Office to Addressee" service under 37 CFR 1.10 and addressed to the Commissioner for Patents, Box Patent Application, Washington, D.C. 20231.

Whitney Taylor
Name of Person Mailing Paper

Whitney Taylor
Signature of Person Mailing Paper

PRELIMINARY AMENDMENT

Dear Sir:

Prior to examination of the above-identified application, please amend the application as follows:

In the claims:

Please cancel claims 1-23, without prejudice, and add new claims 24-50 as follows:

24. An isolated nucleic acid molecule comprising the nucleotide sequence set forth in SEQ ID NO:2, or a complement thereof.

25. An isolated nucleic acid molecule comprising the nucleotide sequence set forth in SEQ ID NO:5, or a complement thereof.

26. An isolated nucleic acid molecule consisting of the nucleotide sequence set forth in SEQ ID NO:2, or a complement thereof.

27. An isolated nucleic acid molecule consisting of the nucleotide sequence set forth in SEQ ID NO:5, or a complement thereof.

28. An isolated nucleic acid molecule which encodes a polypeptide comprising the amino acid sequence set forth in SEQ ID NO:1, or a complement thereof.

29. An isolated nucleic acid molecule which encodes a polypeptide comprising the amino acid sequence set forth in SEQ ID NO:4, or a complement thereof.

30. An isolated nucleic acid molecule which encodes a polypeptide consisting of the amino acid sequence set forth in SEQ ID NO:1, or a complement thereof.

31. An isolated nucleic acid molecule which encodes a polypeptide consisting of the amino acid sequence set forth in SEQ ID NO:4, or a complement thereof.

32. An isolated nucleic acid molecule comprising the nucleotide sequence contained in the plasmid deposited with ATCC® as Accession Number PTA-1143, or a complement thereof.

33. An isolated nucleic acid molecule consisting of the nucleotide sequence contained in the plasmid deposited with ATCC® as Accession Number PTA-1143, or a complement thereof.

34. An isolated nucleic acid molecule comprising a nucleotide sequence having at least 95% sequence identity to the nucleotide sequence shown in SEQ ID NO:2, wherein elevated levels of said nucleic acid molecule are indicative of cardiac myocyte hypertrophy.

35. An isolated nucleic acid molecule comprising a nucleotide sequence having at least 95% sequence identity to the nucleotide sequence shown in SEQ ID NO:5, wherein elevated levels of said nucleic acid molecule are indicative of cardiac myocyte hypertrophy.

36. An isolated nucleic acid molecule consisting of a nucleotide sequence having at least 95% sequence identity to the nucleotide sequence shown in SEQ ID NO:2, wherein elevated levels of said nucleic acid molecule are indicative of cardiac myocyte hypertrophy.

37. An isolated nucleic acid molecule consisting of a nucleotide sequence having at least 95% sequence identity to the nucleotide sequence shown in SEQ ID NO:5, wherein elevated levels of said nucleic acid molecule are indicative of cardiac myocyte hypertrophy.

38. An isolated nucleic acid molecule comprising a nucleotide sequence encoding a fragment of the amino acid sequence shown in SEQ ID NO:1, wherein the fragment comprises at least 35 contiguous amino acids, or a complement thereof.

39. An isolated nucleic acid molecule comprising a nucleotide sequence encoding a fragment of the amino acid sequence shown in SEQ ID NO:4, wherein the fragment comprises at least 35 contiguous amino acids, or a complement thereof.

40. An isolated nucleic acid molecule comprising at least 50 contiguous nucleotides of the nucleotide sequence shown in SEQ ID NO:2 or 5.

41. An isolated nucleic acid molecule consisting of at least 50 contiguous nucleotides of the nucleotide sequence shown in SEQ ID NO:2 or 5.

42. An isolated nucleic acid molecule comprising a nucleotide sequence encoding amino acid 46 to amino acid 312 of SEQ ID NO:1 or 4, or a complement thereof.

43. An isolated nucleic acid molecule comprising a nucleotide sequence encoding amino acid 322 to amino acid 361 of SEQ ID NO:1 or 4, or a complement thereof.

44. An isolated nucleic acid molecule comprising a nucleotide sequence encoding amino acid 125 to amino acid 145 of SEQ ID NO:1 or 4, or a complement thereof.

45. An isolated nucleic acid molecule comprising the nucleic acid molecule of any one of claims 24-43 or 44, and a nucleotide sequence encoding a heterologous polypeptide.

46. A vector comprising the nucleic acid molecule of any one of claims 24-43 or 44.

47. The vector of claim 46, which is an expression vector.

48. An isolated host cell transfected with the vector of claim 46.

49. A method of expressing a polypeptide comprising the step of culturing the isolated host cell of claim 48 under conditions in which the nucleic acid molecule is expressed, thereby expressing the polypeptide.

50. A kit comprising the nucleic acid molecule of any one of claims 24-43 or 44 and instructions for use.

REMARKS

Claims 1-23 were pending in the present application. Claims 1-23 have been canceled, without prejudice, and new claims 24-50 have been added. Accordingly, upon entry of the present amendment, claims 24-50 will be pending. For the Examiner's convenience, the currently pending claims are set forth herein in Appendix A.

Support for new claims 24-50 can be found throughout the specification including the claims as originally filed. Specifically, support for new *claims 24-33* may be found in originally filed claim 3. Support for new *claims 34-37* may be found at, for example, page 43, lines 28-31; page 5, lines 4-16; page 29, lines 2-7; and page 51, lines 25-31 of the specification. Support for new *claims 38-39* may be found at, for example, page 22, lines 23-28 of the specification. Support for new *claims 40-41* may be found at, for example, page 45, lines 5-6 of the specification. Support for new *claims 42-44* may be found at, for example, page 46, lines 1-9 of the specification. Support for new *claim 45* may be found at, for example, page 24, line 28 through page 25, line 2 of the specification. Support for new *claims 46-49* may be found in originally filed claims 6-8. Support for new *claim 50* may be found at, for example, page 57, lines 8-14 of the specification.


No new matter has been added. Any amendments to and/or cancellation of the claims should in no way be construed as an acquiescence to any of the Examiner's rejections and was

done solely to expedite the prosecution of the application. Applicants reserve the right to pursue the claims as originally filed in this or a separate application(s).

CONCLUSION

In view of the amendments and remarks set forth above, it is respectfully submitted that this application is in condition for allowance. If there are any remaining issues or the Examiner believes that a telephone conversation with Applicants' Attorney would be helpful in expediting prosecution of this application, the Examiner is invited to call the undersigned at (617) 227-7400.

Respectfully submitted,
LAHIVE & COCKFIELD, LLP


Maria C. Laccotripe, Ph.D.
Attorney for Applicant
Limited Recognition Under 37 C.F.R. §10.9(b)

28 State Street
Boston, Massachusetts 02109
telephone: (617) 227-7400
facsimile: (617) 742-4214
Date: February 13, 2002

APPENDIX A

24. An isolated nucleic acid molecule comprising the nucleotide sequence set forth in SEQ ID NO:2, or a complement thereof.

25. An isolated nucleic acid molecule comprising the nucleotide sequence set forth in SEQ ID NO:5, or a complement thereof.

26. An isolated nucleic acid molecule consisting of the nucleotide sequence set forth in SEQ ID NO:2, or a complement thereof.

27. An isolated nucleic acid molecule consisting of the nucleotide sequence set forth in SEQ ID NO:5, or a complement thereof.

28. An isolated nucleic acid molecule which encodes a polypeptide comprising the amino acid sequence set forth in SEQ ID NO:1, or a complement thereof.

29. An isolated nucleic acid molecule which encodes a polypeptide comprising the amino acid sequence set forth in SEQ ID NO:4, or a complement thereof.

30. An isolated nucleic acid molecule which encodes a polypeptide consisting of the amino acid sequence set forth in SEQ ID NO:1, or a complement thereof.

31. An isolated nucleic acid molecule which encodes a polypeptide consisting of the amino acid sequence set forth in SEQ ID NO:4, or a complement thereof.

32. An isolated nucleic acid molecule comprising the nucleotide sequence contained in the plasmid deposited with ATCC® as Accession Number PTA-1143, or a complement thereof.

33. An isolated nucleic acid molecule consisting of the nucleotide sequence contained in the plasmid deposited with ATCC® as Accession Number PTA-1143, or a complement thereof.

34. An isolated nucleic acid molecule comprising a nucleotide sequence having at least 95% sequence identity to the nucleotide sequence shown in SEQ ID NO:2, wherein elevated levels of said nucleic acid molecule are indicative of cardiac myocyte hypertrophy.

35. An isolated nucleic acid molecule comprising a nucleotide sequence having at least 95% sequence identity to the nucleotide sequence shown in SEQ ID NO:5, wherein elevated levels of said nucleic acid molecule are indicative of cardiac myocyte hypertrophy.

36. An isolated nucleic acid molecule consisting of a nucleotide sequence having at least 95% sequence identity to the nucleotide sequence shown in SEQ ID NO:2, wherein elevated levels of said nucleic acid molecule are indicative of cardiac myocyte hypertrophy.

37. An isolated nucleic acid molecule consisting of a nucleotide sequence having at least 95% sequence identity to the nucleotide sequence shown in SEQ ID NO:5, wherein elevated levels of said nucleic acid molecule are indicative of cardiac myocyte hypertrophy.

38. An isolated nucleic acid molecule comprising a nucleotide sequence encoding a fragment of the amino acid sequence shown in SEQ ID NO:1, wherein the fragment comprises at least 35 contiguous amino acids, or a complement thereof.

39. An isolated nucleic acid molecule comprising a nucleotide sequence encoding a fragment of the amino acid sequence shown in SEQ ID NO:4, wherein the fragment comprises at least 35 contiguous amino acids, or a complement thereof.

40. An isolated nucleic acid molecule comprising at least 50 contiguous nucleotides of the nucleotide sequence shown in SEQ ID NO:2 or 5.

41. An isolated nucleic acid molecule consisting of at least 50 contiguous nucleotides of the nucleotide sequence shown in SEQ ID NO:2 or 5.

42. An isolated nucleic acid molecule comprising a nucleotide sequence encoding amino acid 46 to amino acid 312 of SEQ ID NO:1 or 4, or a complement thereof.

43. An isolated nucleic acid molecule comprising a nucleotide sequence encoding amino acid 322 to amino acid 361 of SEQ ID NO:1 or 4, or a complement thereof.

44. An isolated nucleic acid molecule comprising a nucleotide sequence encoding amino acid 125 to amino acid 145 of SEQ ID NO:1 or 4, or a complement thereof.

45. An isolated nucleic acid molecule comprising the nucleic acid molecule of any one of claims 24-43 or 44, and a nucleotide sequence encoding a heterologous polypeptide.

46. A vector comprising the nucleic acid molecule of any one of claims 24-43 or 44.

47. The vector of claim 46, which is an expression vector.

48. An isolated host cell transfected with the vector of claim 46.

49. A method of expressing a polypeptide comprising the step of culturing the isolated host cell of claim 48 under conditions in which the nucleic acid molecule is expressed, thereby expressing the polypeptide.

50. A kit comprising the nucleic acid molecule of any one of claims 24-43 or 44 and instructions for use.